GlobalData on MSN2d
EC approves BMS’ Opdivo and Yervoy combo for HCC
The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
Zacks.com on MSN2d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...
BioSpace2dOpinion
Opinion: FDA Faces Challenging Decision on Biomarker-Based Label Restrictions
The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...
Pharmabiz2d
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...
Cure Today16d
Neoadjuvant Opdivo Combo Elicits Statistically Significant OS Findings in Resectable NSCLC
CheckMate-816 is a randomized, open-label, multi-center trial which is evaluating the efficacy of Opdivo in combination with chemotherapy versus chemotherapy alone as a neoadjuvant treatment for ...
CURE8d
Checkpoint Inhibitor Therapy and ISRT Maintains Outcomes in Younger Patients With cHL
Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients ...
Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...
pharmaphorum6d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
It covers all indications on the current Opdivo label for adults with solid tumours, including as monotherapy, for maintenance following completion of the checkpoint inhibitor plus Yervoy ...